FDA Approves Foundayo: A Modern Once-Daily Oral GLP-1 for Weight Management
Weight loss treatment is shifting away from the needle. On April 1, 2026, the U.S. Food and Drug Administration (FDA) approved Foundayo (orforglipron), a daily oral medication developed by Eli Lilly and Company. This approval provides a new option for adults struggling with obesity or those who are overweight with weight-related medical problems.
Unlike many previous GLP-1 therapies that require weekly injections, Foundayo is a tablet. This represents a significant step in making weight management more accessible for patients who prefer oral medication over injectable alternatives.
What is Foundayo?
Foundayo is a glucagon-like peptide-1 (GLP-1) receptor agonist. It’s designed to be used in combination with an increased physical activity routine and a reduced-calorie diet to facilitate adults reduce excess body weight and maintain that reduction over the long term.
The medication is specifically indicated for:
- Adults with obesity.
- Adults with overweight who have at least one weight-related comorbid condition.
How Foundayo Differs from Other GLP-1s
While the market has seen a surge in GLP-1 medications, Foundayo offers distinct advantages in administration. It is a once-daily pill that can be taken at any time of the day. Crucially, it carries no food or water restrictions, making it easier to integrate into a daily routine compared to some other oral options.
Foundayo is the second oral GLP-1 drug to enter the market this year, following the introduction of Novo Nordisk’s Wegovy pill in January 2026.
Clinical Efficacy and Dosage
Research studies indicate that Foundayo is effective for significant weight reduction. Participants in these studies lost an average of about 25 pounds over a 72-week period. Those taking the highest dose of 17.2 milligrams per day saw an average weight loss of approximately 27 pounds over the same 72-week duration.
To allow for personalized treatment, Foundayo is available in six different dosage strengths:
- 0.8 mg
- 2.5 mg
- 5.5 mg
- 9 mg
- 14.5 mg
- 17.2 mg
A Historic Approval Process
The approval of Foundayo marks a milestone for the FDA’s regulatory process. It is the first new molecular entity (NME) approved under the Commissioner’s National Priority Voucher (CNPV) pilot program. This program, launched in 2025, aims to expedite the approval of applications that address critical national health priorities.
Since of this priority review, the FDA issued its decision just 50 days after filing—nearly 300 days before the original PDUFA date of January 20, 2027. This makes it the fastest approval of a new molecular entity since 2002.
Key Takeaways
| Feature | Foundayo (orforglipron) Details |
|---|---|
| Administration | Once-daily oral tablet |
| Requirements | No food or water restrictions; take any time of day |
| Average Weight Loss | ~25 lbs (up to 27 lbs on max dose) over 72 weeks |
| Available Doses | 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, 17.2 mg |
| Manufacturer | Eli Lilly and Company |
Looking Ahead
The arrival of Foundayo adds a critical tool to the obesity treatment toolkit, particularly for patients who are averse to injections or the logistical challenges of refrigerated medications. As more oral GLP-1 options grow available, the focus for clinicians and patients will shift toward finding the specific delivery method and dosage that best supports long-term weight maintenance and overall health.